Applied Genetic Technologies logo

AGTC - Applied Genetic Technologies News Story

$4.14 0.0  0.0%

Last Trade - 7:35pm

Small Cap
Market Cap £127.4m
Enterprise Value £54.8m
Revenue £n/a
Position in Universe 4799th / 6938

AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial

Thu 6th May, 2021 12:00pm
For best results when printing this announcement, please click on link below:

-Groups 5 and 6 had a 50% response rate among patients who met the inclusion
criteria for the Skyline and Vista trials-

-Best Corrected Visual Acuity (BCVA) data continue to provide supportive
evidence of biological response at 12 months-

-Data from a subset of Group 4 patients available for analysis at 24 months
also provide preliminary evidence of continued durable responses and continue
to demonstrate a favorable safety profile-

-Conference call to review data today at 8:00 AM EDT-

GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) --
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology
company conducting human clinical trials of adeno-associated virus (AAV)-based
gene therapies for the treatment of rare retinal diseases, today reported
additional positive data from the ongoing X-linked retinitis pigmentosa (XLRP)
Phase 1/2 clinical trial, including 12-month data from Groups 5 and 6
reflecting a 50% response rate among patients who met the inclusion criteria
for the Skyline and Vista trials and 24-month data from two of three Group 4
patients providing preliminary evidence of response durability. The third
patient was not a responder at Month 12 and no early data are currently
available for the remaining four Group 4 patients. Taken together, these data
add to the body of evidence suggesting that durable improvements in visual
sensitivity and visual acuity may be achieved in patients receiving AGTC’s
XLRP product candidate while continuing to demonstrate a favorable safety

“The rate and durability of response for improvements in retinal sensitivity
are very promising, as are continued trends of increased visual acuity at
Month 12 in some patients,” said Robert Sisk, MD, Associate Professor of
Ophthalmology, University of Cincinnati and Cincinnati Eye Institute, and an
investigator on AGTC’s XLRP Phase 1/2 clinical trial. “Gene therapy holds
great promise in improving outcomes for these early and moderate staged XLRP
patients, who today have no FDA-approved treatment options. I believe that the
data presented today are an important advance for the field of gene therapy
for retinitis pigmentosa, and I look forward to presenting the full Month 12
Phase 1/2 data at the American Academy of Ophthalmology annual meeting later
this year.”

“A growing body of data supports the best-in-class potential of our XLRP
therapy product candidate and we are executing a robust plan to advance this
program as rapidly as possible toward commercialization,” said Sue Washer,
President and CEO of AGTC. “The 50% response rate observed in Groups 5 and
6, coupled with the 12-month visual sensitivity and visual acuity data from
these groups and 24-month data from three Group 4 patients, position the Phase
2/3 Vista trial and expanded Phase 1/2 Skyline trials for success. The clear
differences in visual sensitivity and visual acuity between the treated and
untreated eyes at 12 months in Groups 5 and 6 demonstrate a biological
response to our XLRP candidate.”

Groups 5 and 6 Month 12 Data
Data at 12 months were available from seven patients in Group 5 and four
patients in Group 6. One patient in Group 5 and two patients in Group 6 would
not meet the inclusion criteria for the Skyline and Vista trials, resulting in
a total of eight patients who were included in the responder analysis. Four of
these eight patients (50%) were considered responders, all four of whom met
the strict criteria of at least a 7 decibel (dB) improvement in at least 5
loci. One additional patient did not meet these criteria but had a
statistically significant improvement in retinal sensitivity in the treated
compared with the untreated eye at 12 months.

Consistent with previously reported 6-month data from Groups 2, 4, 5 and 6,
assessment of BCVA in these groups at 12 months continue to provide supportive
evidence of improved visual acuity in these patients; the difference between
treated and untreated eyes is statistically significant. The Company believes
that these data, together with the favorable safety profile, differentiate its
XLRP candidate from competitors.

Group 4 Month 24 Data
Data from three of the seven Group 4 patients were available for analysis at
Month 24, including two who were responders at Month 12 (one by the 7dB change
in at least 5 loci response criteria and the other based on improved retinal
sensitivity in the treated compared with the untreated eye). These two
patients are still responders at Month 24 according to the same criteria; the
third patient who has reached Month 24 was not a responder at Month 12 or
Month 24. To the best of the Company’s knowledge, this is the first XLRP
gene therapy clinical trial to demonstrate continued durability of response at
this time point.

Safety Data
Data from all 28 patients across six dose groups continue to demonstrate a
favorable safety profile with no dose-limiting inflammatory responses
observed. This safety profile, which has shown no clinically significant
inflammation not manageable with steroids, continues to be observed out to 24

Upcoming XLRP Clinical Milestones
AGTC believes it has a best-in-class XLRP product candidate that may provide
significant benefit to patients with XLRP. The Company expects to:
* Present 12-month trial results from the ongoing Phase 1/2 clinical trial at
the American Academy of Ophthalmology Annual Meeting in November 2021;
* Provide Skyline trial results from the 3-month masked interim analysis in 4Q
* Provide Skyline trial results from the 12-month data in 3Q 2022; and
* Provide Vista trial results from the 6-month masked interim analysis in 4Q
Conference Call and Webcast
AGTC will host a conference call and webcast to discuss the 12-month data from
Groups 5 and 6 and 24-month data from Group 4 from its ongoing Phase 1/2 XLRP
clinical trial today at 8:00am ET. To access the call, dial 866-269-4262 (US)
or 323-347-3278 (outside of the US) referencing conference ID# 9770776. A live
webcast will be available in the Events and Presentations section of AGTC’s
Investor Relations site at Please
log in approximately 10 minutes prior to the scheduled start time.

The archived webcast will be available in the Events and Presentations section
of the Company's website.

About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies
for people with rare and debilitating ophthalmic, otologic and central nervous
system (CNS) diseases. AGTC is a leader in designing and constructing all
critical gene therapy elements and bringing them together to develop
customized therapies that address real patient needs. AGTC’s most advanced
clinical programs leverage its best-in-class technology platform to
potentially improve vision for patients with an inherited retinal disease.
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and
achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on
the Company’s industry leading AAV manufacturing technology and scientific
expertise. AGTC is advancing multiple important pipeline candidates to address
substantial unmet clinical need in optogenetics, otology and CNS disorders. In
recent years AGTC has entered into strategic partnerships with companies
including Otonomy, a biopharmaceutical company dedicated to the development of
innovative therapeutics for neurotology, and Bionic Sight, an innovator in
the emerging field of optogenetics and retinal coding. 

Forward-Looking Statements
This release contains forward-looking statements that reflect AGTC's plans,
estimates, assumptions and beliefs, including statements regarding the
projected timing for its planned Vista (Phase 2/3 XLRP) and Skyline (Expanded
Phase 1/2) clinical trials, the timing for reporting data in both its Skyline
and Vista trials. Forward-looking statements include information concerning
possible or assumed future results of operations, financial guidance, business
strategies and operations, preclinical and clinical product development and
regulatory progress, potential growth opportunities, potential market
opportunities, the effects of competition and the impact of the COVID-19
pandemic, including the impact on its ability to enroll patients.
Forward-looking statements include all statements that are not historical
facts and can be identified by terms such as "anticipates," "believes,"
"could," "seeks," "estimates," "expects," "intends," "may," "plans,"
"potential," "predicts," "projects," "should," "will," "would" or similar
expressions and the negatives of those terms. Actual results could differ
materially from those discussed in the forward-looking statements, due to a
number of important factors. Risks and uncertainties that may cause actual
results to differ materially include, among others: gene therapy is still
novel with only a few approved treatments so far; AGTC cannot predict when or
if it will obtain regulatory approval to commercialize a product candidate or
receive reasonable reimbursement; uncertainty inherent in clinical trials and
the regulatory review process; risks and uncertainties associated with drug
development and commercialization; the direct and indirect impacts of the
ongoing COVID-19 pandemic on our business, results of operations, and
financial condition; factors that could cause actual results to differ
materially from those described in the forward-looking statements are set
forth under the heading "Risk Factors" in our most recent annual or quarterly
report and in other reports we have filed with the SEC. Given these
uncertainties, you should not place undue reliance on these forward-looking
statements. Also, forward-looking statements represent management's plans,
estimates, assumptions and beliefs only as of the date of this release. Except
as required by law, we assume no obligation to update these forward-looking
statements publicly or to update the reasons actual results could differ
materially from those anticipated in these forward-looking statements, even if
new information becomes available in the future.

David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485 or

Corporate Contacts:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754


GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.